nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.02.2017 | short review

Milestones in advanced renal cell carcinoma

verfasst von: Dora Niedersuess-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Summary

Renal cell carcinoma (RCC) is a common tumor that is largely refractory to cytotoxic agents. With the implementation of a multitude of novel therapies in the past 10 years, the overall survival of patients with advanced RCC has more than doubled.

Vorheriger Artikel Milestones in gastric cancer

Nächster Artikel Milestones in pathology—from histology to molecular biology

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2015;136:E359–86.CrossRefPubMed

Kroeger N, Choueiri T, Lee J, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65:1086–92.CrossRefPubMed

Baldewijns M, Van Vlodrop I, Vermeulen P, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38.CrossRefPubMed

Klatte T, Pantuck A. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008;35:573–80.CrossRefPubMed

Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefPubMed

Lee J, Kim M, Park I, et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300–5.CrossRefPubMed

Rini B, Wood L, Elson P, et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (Pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting. J Clin Oncol. 2013;31(Suppl; abstr 4515).

Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013;369:722–31.CrossRefPubMed

Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412–8.CrossRefPubMed

10.

Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.CrossRefPubMed

11.

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.CrossRefPubMed

12.

Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.CrossRefPubMed

13.

Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906.CrossRefPubMed

14.

Voss M, Molina A, Motzer R. M TOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25:835–52.CrossRefPubMedPubMedCentral

15.

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.CrossRefPubMed

16.

Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.CrossRefPubMed

17.

Grullich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:207–14.CrossRefPubMed

18.

Zhou L, Liu X, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–97.CrossRefPubMed

19.

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol. 2016;17:917–27.CrossRefPubMed

20.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68.CrossRefPubMed

21.

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–82.CrossRefPubMed

22.

Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and metaanalysis. Eur Urol. 2015;67:740–9.CrossRefPubMed

23.

Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomisedphase 2 trial. Lancet Oncol. 2016;17:378–88.CrossRefPubMed

24.

Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.CrossRefPubMed

25.

Ravaud A, Motzer R, Pandha H, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–54.CrossRefPubMed

26.

Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–16.CrossRefPubMed

27.

Fyfe GA, Fisher RI, Rosenberg SA, et al. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high dose recombinant interleukin 2 therapy. J Clin Oncol. 1996;14:2410–1.CrossRefPubMed

28.

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMed

29.

ClinicalTrials.gov. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) 2014. http://clinicaltrials.gov/ct2/show/NCT02231749. Accessed 04.01.2017

Titel: Milestones in advanced renal cell carcinoma
verfasst von: Dora Niedersuess-Beke
Publikationsdatum: 01.02.2017
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-017-0321-9

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Milestones of the last 10 years

My personal highlights of ESMO 2016

To print or not to print

Milestones in gastric cancer

memo: Spectacular developments during the last decade from the Section Editors’ point of view

Milestones in myeloma